PreprintPDF Available

Amino Acid L-Lysine SARS-CoV-2 (COVID-19) Prophylaxis

Preprints and early-stage research may not have been peer reviewed yet.


The over the counter amino acid L-Lysine has now been shown in the small group reported here to be an extremely effective prophylaxis regimen against SARS-CoV-2.
Amino Acid L-Lysine SARS-CoV-2 (COVID-19) Prophylaxis
The over the counter amino acid L-Lysine has now been shown in the small group reported
here to be an extremely effective prophylaxis regimen against SARS-Co-V-2.
The first report of the therapeutic effect of L-Lysine on SARS-CoV-2 by the Bio-Virus
Research team was published in ResearchGate this year. (1)
This second report addresses its prophylactic use.
30 medical professionals at Salud Publica (public health) Department in Santiago,
Dominican Republic, following the suggestion and advice of a member of the Bio-Virus
team, self-administered the L-Lysine treatment protocol referenced above (1) of 2 gms per
day of lysine with the required dietary restrictions. The study was conducted by the director
of the district after she reviewed the data of the anti-viral properties of lysine, performed
her own due diligence, and decided to try it in their sector. Less than 24 hours after first
distributing L-Lysine to the first 18 patients, positive results gave the director the confidence
to present this information to all sector employees as a prophylaxis regimen. After three
months, through the spring to summer peak of COVID-19 cases in the Dominican Republic,
with daily face-to-face exposure to SARS-CoV-2 patients, not a single doctor, nurse, or staff
member fell ill or tested positive. They were tested once weekly with the current rapid test.
In the months prior to L-Lysine prophylaxis, an average of two employees fell ill per month,
and a comparison of similar sized public health departments had reported their staff
routinely falling ill during the same period. Several other individual cases, with confirmed
positive exposure living in close quarters and with no isolation possible proved lysine to be
an excellent prophylaxis, or post exposure treatment if taken within 24 hours of exposure.
The few failures reported were underdosed for weight or did not follow the essential dietary
restrictions. A detailed explanation of the protocols, dietary restrictions, and cautions are
given in the initial paper. Lysine, for example, should not be used by those with HIV, and
used only with proper monitoring by those with autoimmune diseases, pacemakers or high
calcium levels.
Our results strongly suggest that frontline healthcare workers would find a new level of
protection by using L-Lysine prophylactically. More extensive studies are required to confirm
these findings and establish proper dosage protocols.
... Among 30 medical professionals with daily face-to-face exposure to COVID-19 patients, all remain negative of the virus after taking 2000 mg lysine daily with required dietary restrictions (no caffeine, marijuana and arginine-rich foods) for 3 months, as compared to an average of two employees being infected every month prior to the study and to a public health department with similar capacity as their control group [39]. Our study validates that lysine has protective effects against SARS-CoV-2 and IAV infection. ...
Full-text available
Amino acids have been implicated with virus infection and replication. Here, we demonstrate the effects of two basic amino acids, arginine and lysine, and their ester derivatives on infection of two enveloped viruses, SARS-CoV-2, and influenza A virus. We found that lysine and its ester derivative can efficiently block infection of both viruses in vitro. Furthermore, the arginine ester derivative caused a significant boost in virus infection. Studies on their mechanism of action revealed that the compounds potentially disturb virus uncoating rather than virus attachment and endosomal acidification. Our findings suggest that lysine supplementation and the reduction of arginine-rich food intake can be considered as prophylactic and therapeutic regimens against these viruses while also providing a paradigm for the development of broad-spectrum antivirals.
ResearchGate has not been able to resolve any references for this publication.